First oral drug for advanced or metastatic bladder cancer.
Lisa M. Holle, PharmD, BCOP, FHOPA
Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
New developments in cancer treatment require medication experts—here's how you can become that expert.
FDA approves apalutamide for castration-resistant prostate cancer.
Emicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.
A new era of treatment has arrived—here’s what you need to know.
The New Drug Review for April
Here: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.
New drug review
FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone